Precision BioSciences Inc
PBS0
Company Profile
Business description
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Contact
302 East Pettigrew Street
Dibrell Building, Suite A-100
DurhamNC27701
USAT: +1 919 314-5512
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
67
Stocks News & Analysis
stocks
ASX healthcare giant remains well positioned despite share slump
We welcome the CEO change at CSL but relatively soft plasma performance will postpone recovery
stocks
Australian bank remains overvalued despite strong result
When strong fundamentals meet persistent valuation headwinds.
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
The latest take from our equity research analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 41.30 | -0.44% |
| CAC 40 | 8,403.89 | 90.65 | 1.09% |
| DAX 40 | 25,157.55 | 301.40 | 1.21% |
| Dow JONES (US) | 49,640.92 | 480.48 | -0.96% |
| FTSE 100 | 10,463.00 | 9.11 | -0.09% |
| HKSE | 27,032.54 | 233.84 | -0.86% |
| NASDAQ | 22,681.30 | 385.16 | -1.67% |
| Nikkei 225 | 57,639.84 | 10.70 | -0.02% |
| NZX 50 Index | 13,531.48 | 24.20 | 0.18% |
| S&P 500 | 6,862.42 | 79.05 | -1.14% |
| S&P/ASX 200 | 9,043.50 | 18.50 | -0.20% |
| SSE Composite Index | 4,134.02 | 2.03 | 0.05% |